Key Developments: Wright Medical Group Inc (WMGI.MW)

WMGI.MW on Midwest Stock Exchange

26.20USD
23 Apr 2015
Change (% chg)

-- (--)
Prev Close
$26.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,308
52-wk High
$32.49
52-wk Low
$24.35

Search Stocks

Latest Key Developments (Source: Significant Developments)

Wright Medical Group, Inc gives FY 2015 guidance
Wednesday, 25 Feb 2015 05:44pm EST 

Wright Medical Group, Inc:Anticipates net sales for FY 2015 of about $325 million to $335 million, representing constant currency growth of 13 pct. to 16 pct. from FY 2014.Sees FY 2015 adjusted EBITDA from continuing operations, as described in the GAAP to non-GAAP reconciliation provided later in this release, of negative $(22.0) million to negative $(27.0) million.Anticipates adjusted earnings per share from continuing operations, including stock-based compensation, for FY 2015 of $(1.67) to $(1.77) per diluted share, based on about 51.1 million shares outstanding.  Full Article

Wright Medical Group Inc. prices $550 million cash convertible senior notes offering
Tuesday, 10 Feb 2015 07:00am EST 

Wright Medical Group Inc:Says pricing of its offering of $550 million aggregate principal amount of cash convertible senior notes due 2020.Company also granted the initial purchasers a 30-day option to purchase up to an additional $82.5 million aggregate principal amount of notes solely to cover over-allotments.The offering is expected to close on February 13, subject to customary closing conditions.Notes will be senior unsecured obligations and pay interest semiannually in arrears at a rate of 2.00% per annum on February 15 and August 15 of each year, beginning on August 15.Prior to August 15, 2019, the notes will be convertible into cash at the option of the holder under certain conditions and, thereafter until the close of business on the business day immediately preceding the maturity date, at any time.The notes mature on Feb.15, 2020.  Full Article

Wright Medical Group Inc announces proposed private placement of cash convertible senior notes
Monday, 9 Feb 2015 07:00am EST 

Wright Medical Group Inc:Intention to commence an offering, subject to market and other conditions, of $400 mln aggregate principal amount of cash convertible senior notes due 2020.Intends to grant initial purchasers 30-day option to purchase up to an additional $60 mln aggregate principal amount of notes solely to cover over-allotments.Estimates that net proceeds of offering will be about $389 mln.Expects to use portion of net proceeds to pay cost of cash convertible note hedge transactions.Intends to use remaining net proceeds from offering for general corporate purposes, including possible acquisitions and to repay up to about $250 mln aggregate principal amount of company's outstanding indebtedness in privately negotiated transactions.  Full Article

Wright Medical Group gives Q4 2014 revenue guidance in line with analysts' estimates; sees FY 2014 revenue guidance at the low end of prior range
Monday, 12 Jan 2015 06:00am EST 

Wright Medical Group Inc:Expects Q4 2014 revenue of about $83.3 mln.Expects FY 2014 revenue to be about $298.0 mln.Q4 2014 revenue of $84 mln - Thomson Reuters I/B/E/S.FY 2014 revenue of $298 mln - Thomson Reuters I/B/E/S.  Full Article

Wright Medical Group lowers FY 2014 revenues guidance
Monday, 27 Oct 2014 04:16pm EDT 

Wright Medical Group, Inc:Updates FY 2014 revenue guidance to be in the range of $298 mln to $302 mln, compared to previous guidance of $308 mln to $312 mln.FY 2014 revenues of $309 mln - Thomson Reuters I/B/E/S.  Full Article

Wright Medical Group Inc announces receipt of FDA approvable letter for Augment Bone Graft
Monday, 27 Oct 2014 04:16pm EDT 

Wright Medical Group Inc:Announced that its BioMimetic subsidiary has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for its Premarket Approval Application (PMA) for Augment Bone Graft.Says the approvable letter indicates that FDA determined Augment Bone Graft to be safe and effective as an alternative to autograft for ankle and/or hindfoot fusion indications and is approvable subject to customary preapproval facilities inspections.  Full Article

Wright Medical Group Inc appoints Kevin D. Cordell as President
Monday, 15 Sep 2014 04:00pm EDT 

Wright Medical Group Inc:Says that Kevin D. Cordell has been appointed President, U.S. Extremities, effective Sept. 29, 2014.  Full Article

Wright Medical Group Inc reiterates FY 2014 outlook
Tuesday, 5 Aug 2014 04:00pm EDT 

Wright Medical Group Inc:Reiterates FY 2014 its previous guidance range for net sales from continuing operations of about $308 to $312 million.Also reiterates FY 2014 adjusted EBITDA from continuing operations of $(20.0) to $(15.0) million.Reiterates FY 2014 adjusted earnings per share from continuing operations, including stock-based compensation, of $(1.28) to $(1.38) per diluted share.FY 2014 revenue of $310 mln, EBITDA of $(13.94 ) mln and EPS of $(1.32) - Thomson Reuters I/B/E/S.  Full Article

Wright Medical Group Inc raises low end of FY 2014 revenue outlook to a range in line with analysts' estimates, reiterates EBITDA outlook, gives EPS outlook below analysts' estimates
Wednesday, 30 Apr 2014 04:03pm EDT 

Wright Medical Group Inc:Now expects FY 2014 net sales from continuing operations, or Extremity and Biologics revenue, of about $308 to $312 million (previous $305 to $312 million).Reiterates previously issued adjusted EBITDA from continuing operations of $(20.0) million to $(15.0) million.Adjusted earnings per share from continuing operations, including stock-based compensation, to be in the range of $(1.28) to $(1.38) per diluted share.FY 2014 revenue of $309 mln, EBITDA of $(16.31) mln and EPS of $(1.43) - Thomson Reuters I/B/E/S.  Full Article

Wright Medical Group Inc gives FY 2014 mixed guidance
Monday, 24 Feb 2014 04:00pm EST 

Wright Medical Group Inc:Expects FY 2014 net sales from continuing operations, or extremity and biologics revenue, to be in the range of $305 million to $312 million.Projects FY 2014 adjusted EBITDA from continuing operations, in the range of negative $(20.0) million to negative $(15.0) million.FY 2014 revenue of $279 million and EBITDA of $(11) million - Thomson Reuters I/B/E/S.  Full Article

Search Stocks